Numinus has announced a Phase 1 trial of a natural psilocybin product extracted and formulated at its company lab. The Vancouver-based company hopes that successful completion of the trial would allow for the product to be researched further via special access or compassionate access programs. “We believe there are several likely advantages to naturally occurring Psilocybintherapeutics that will…


Previous articleRed Light Holland and Headland West Indies Lead #SVGStrong, a Relief Effort in St. Vincent and the Grenadines
Next articleMydecine to Report Full Year 2020 Financial Results on May 3, 2021